NCT00363870View on ClinicalTrials.gov

A Study to Demonstrate the Efficacy of GSK Biologicals' Influenza Vaccine in Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

7,632

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
Influenza
Interventions
BIOLOGICAL

Fluarix vaccine

Trial Locations (15)

15140

GSK Investigational Site, Lahti

20520

GSK Investigational Site, Turku

28120

GSK Investigational Site, Pori

33100

GSK Investigational Site, Tampere

48600

GSK Investigational Site, Kotka

60100

GSK Investigational Site, Seinäjoki

70100

GSK Investigational Site, Kuopio

90100

GSK Investigational Site, Oulu

500 03

GSK Investigational Site, Hradec Králové

02100

GSK Investigational Site, Espoo

00100

GSK Investigational Site, Helsinki

00930

GSK Investigational Site, Helsinki

04400

GSK Investigational Site, Järvenpää

01300

GSK Investigational Site, Vantaa

01600

GSK Investigational Site, Vantaa

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00363870 - A Study to Demonstrate the Efficacy of GSK Biologicals' Influenza Vaccine in Adults | Biotech Hunter | Biotech Hunter